Life Sciences

What Life Sciences does

Life Sciences is an alternative investment sub-strategy offered within Goldman Sachs Asset Management's G-Series platform, alongside Private Equity, Private Credit, Infrastructure, Real Estate, and Secondaries. Per its stated focus, the strategy invests in early-stage innovators in oncology, neurology, rare diseases, and vision, with explicit emphasis on artificial intelligence and gene therapy as thematic lenses. Operationally, it is not a standalone legal entity but a business unit within Goldman Sachs Asset Management, itself a wholly-owned operating division of The Goldman Sachs Group, Inc. (NYSE: GS); no separate incorporation, management roster, or financial disclosures are published for the sub-strategy.

The sub-strategy runs on Goldman Sachs Asset Management's broader investment platform, which combines active portfolio management with quantitative technology, including Data Enhanced Active ETFs that systematically evaluate thousands of stocks across hundreds of indicators using over a trillion data points. Distribution and servicing rely on the parent's global infrastructure: dedicated institutional relationship teams serve pension funds, insurers, and consultants; financial intermediaries (RIAs, broker-dealers, wirehouses, wealth managers, private banks) distribute products; and qualified individual investors access alternatives via the G-Series platform through wealth advisors, with regional hubs in New York, London, Amsterdam, Hong Kong, Singapore, Sydney, and Zurich.

Revenue mechanics for the underlying platform are fee-based, generated through annual expense ratios and management fees on assets under supervision, with additional economics from alternatives products. Parent-level scale is substantial: $3.3+ trillion in firmwide AUS and $627 billion in alternative AUS as of December 31, 2025, supported by 1,700+ investment professionals firmwide and 1,000+ in alternatives. Life Sciences-specific revenue, AUM, fees, and team composition are not separately disclosed.

Name

Life Sciences

Legal name

Life Sciences (Goldman Sachs Asset Management)

Website

https://am.gs.com

Company type

Private

Operating status

Operating

Short description

Life Sciences is an alternative investment sub-strategy within Goldman Sachs Asset Management's G-Series platform, investing in early-stage innovators in oncology, neurology, rare diseases, and vision through AI and gene therapy themes, distributed to institutional and qualified individual investors via Goldman Sachs' global platform.

Ownership category

akta.pro rank

Product category

Alternative Investment Management

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Life sciences investing
• Healthcare venture capital
• Biotech private equity
• Alternative investment strategies
• Early-stage healthcare investments

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Asset Management Fees: Goldman Sachs Asset Management generates revenue primarily through management fees charged on assets under supervision. Fees are typically calculated as an annual expense ratio applied to assets under management across mutual funds, ETFs, and separately managed accounts.
2. ETF Expense Ratios: Exchange-traded funds charge annual expense ratios that cover portfolio management and operating costs. Active ETFs may carry higher expense ratios than passive ETFs but are typically more cost-effective than similar active mutual funds.
3. Private Markets Investment Products: The G-Series platform offers evergreen strategies across private credit, private equity, infrastructure, real estate, and secondaries for qualified investors, generating fees from alternative investment management.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Life Sciences is an evergreen alternative investment strategy offered under Goldman Sachs Asset Management's alternatives platform. It invests in early-stage innovators in oncology, neurology, rare diseases, and vision, with artificial intelligence and gene therapy as core themes. The strategy is part of the G-Series suite providing qualified investors access to private market opportunities.

Product overview

Goldman Sachs Asset Management offers a comprehensive suite of investment products organized across two primary platforms: Public Investing and Alternative Investing (G-Series). The Public Investing platform encompasses Active ETFs (including Premium Income ETFs, Data Enhanced ETFs, Municipal Income ETFs, Fixed Income ETFs, and Fundamental Equity ETFs), along with Fixed Income, Public Equity, Multi-Asset Solutions, Model Portfolios, and Direct Indexing. The Alternative Investing platform provides the G-Series suite of evergreen strategies including Private Credit, Private Equity, Infrastructure, Real Estate, Secondaries, and Life Sciences. The Active ETF lineup includes specific funds such as GIEQ (Data Enhanced International Equity), GPIX (S&P 500 Premium Income), GPIQ (Nasdaq-100 Premium Income), GMUB (Municipal Income), GSGO (Growth Opportunities), GSST (Ultra Short Bond), and GSC (Small Cap Equity), all managed with active investment approaches combining professional portfolio management with the structural advantages of ETFs.

Differentiator

Problem solved

Functional benefit

Products and services

• Life Sciences

Quantifiable outcome

• Active fixed income capabilities backed by $1.7+ trillion in assets under supervision with 30+ year track record
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• InnovatorcoreStrategic or Co-development PartnerGoldman Sachs Asset Management partnered with Innovator to provide Defined Outcome ETFs, combining the pioneering defined outcome ETF strategies with expanded global scale, deep intellectual capital, and a comprehensive suite of investment solutions across public and private markets. The partnership offers advisors a single powerful partner for accessing buffer strategies and defined outcome products.

Scale indicators12 records

Expansion highlights5 records

Direct peers

• Bain Capital Life Sciences: Dedicated life sciences franchise of Bain Capital investing across biotech, medtech, and pharma services at venture, growth, and public-equity stages. Directly comparable given its multi-stage life sciences mandate and institutional capital base.
• OrbiMed Advisors: One of the largest dedicated healthcare and life sciences investment firms globally, managing public and private equity, private credit, and royalty strategies across therapeutic areas. Directly comparable to GSAM Life Sciences as a healthcare-focused growth investor with deep scientific domain expertise.
• Frazier Healthcare Partners: Healthcare-dedicated investment firm operating Growth Equity and Life Sciences buyout and venture strategies. Comparable given its life sciences venture and growth equity mandates and therapeutic-area focus.
• RA Capital Management: Healthcare-focused crossover fund investing across public and private life sciences companies, often leading private rounds and participating in follow-on financings. Comparable as a life sciences growth/crossover investor.
• Atlas Venture: Early-stage life sciences venture firm focused on building biotech companies from inception through clinical proof-of-concept. Comparable as a specialist early-stage life sciences investor, though typically at the formation/seed stage rather than later growth rounds.
• ARCH Venture Partners: Early-stage venture firm focused on founding and building life sciences and technology companies from breakthrough science. Comparable as a specialist early-stage life sciences investor with a focus on transformative technologies including gene therapy.

Broad incumbents

• Blackstone Life Sciences: Life sciences franchise of Blackstone focused on drug development, medical devices, and healthcare growth equity. Comparable as a large-scale institutional life sciences investor, though backed by the broader Blackstone alternatives platform.
• TPG Capital (Healthcare): Healthcare-focused growth and buyout investing within TPG's broader alternatives platform. Comparable as a large multi-strategy investor with a dedicated life sciences practice, though healthcare is one segment among many.
• KKR Health Care Strategic Growth: Growth equity strategy of KKR focused on healthcare and life sciences companies. Comparable as a growth-stage healthcare investor within a broad alternatives platform, though KKR's healthcare practice is one of many verticals.

Emerging players

• New Enterprise Associates (NEA): Large multi-stage venture firm with a dedicated healthcare and life sciences practice investing across biotech, medtech, and healthtech. Comparable as a growth-stage life sciences investor, though NEA is a multi-sector VC rather than a life sciences specialist.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Life Sciences